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e aim of study was to develop and validate two simple, sensitive, and extraction-free spectrophotometric methods for the
estimation of risperidone in both pure and pharmaceutical preparations. ey are based on the charge transfer complexation
reactions between risperidone (RSP) as n-electron donor and p-chloranilic acid (p-CA) inmethodA and 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone (DDQ) in method B as 𝜋𝜋-acceptors. In method A, RSP reacts with p-CA in methanol to produce a bright pink-
colored chromogen measured at 530 nm whereas, in method B, RSP reacts with DDQ in dichloromethane to form orange-colored
complex with a maximum absorption at 460 nm. Beer’s law was obeyed in the concentration range of 0–25 and 0–50 𝜇𝜇g/mL with
molar absorptivity of 1.29 × 104 and 0.48 × 104 L/moL/cm for RSP in methods A and B, respectively.e effects of variables such as
reagents, time, and stability of the charge transfer complexes were investigated to optimize the procedures. e proposed methods
have been successfully applied to the determination of RSP in pharmaceutical formulations. Results indicate that the methods are
accurate, precise, and reproducible (relative standard deviation <2%).
1. Introduction
Risperidone (RSP) chemically known as 4-[2-[4-(6-
�uorobenzo[d]isoxazole-3-yl)-1-piperidyl]ethyl]-3-methyl-
2,6-diazabicyclo[4.4.0]deca-1,3-dien-5-one (Figure 1), is the
atypical antipsychotic drug with a relatively low incidence
of extra pyramidal side effects. It is used for the treatment
of schizophrenia, bipolar disorder, and behavior problems
in people with autism. In 2003, the FDA-approved RSP for
the short-term treatment of the mixed and manic states
associated with bipolar disorder. It is also approved for
the treatment of irritability in children and adolescents
with autism in 2006. e drug is officially included in 2005
European Pharmacopeia, and the official method of its deter-
mination is high-performance liquid chromatography [1].
Many methods have been employed for the determi-
nation of RSP in biological samples including HPLC with
electrochemical detection [2, 3] and RP-HPLC with UV
detection [4]. e most extensively used technique for its
determination is LC-MS/MS, but several procedures using
this technique are con�ned to biological �uids like human
plasma [5–8], plasma andurine [9], and serum [10]. A limited
number of analytical methods for the quantitative estimation
of RSP in pharmaceutical samples are known. Procedures
based on high-performance liquid chromatography and thin-
layer densitometric methods [11], spectrophotometry [12,
13], and gas chromatography [14] are available in the lit-
erature. e reported chromatographic techniques [11, 14]
require expensive experimental setup, whereas the cited
spectrophotometric methods: one is uv method [12] and
another [13] requires extraction step for RSP determination.
us, there is a need to develop sensitive, accurate, and
economical methods for its determination.
In the present study, the authors have described the
development and validation of two simple and sensitive
spectrophotometric methods for the analysis of RSP in pure
form and in pharmaceutical samples using p-CA and DDQ
as 𝜋𝜋-acceptors. e developed methods were validated for
linearity, accuracy, and precision.








F 1: Structure of risperidone.
2. Experimental Section
2.1. Apparatus. All absorbance measurements were per-
formedusing a SystronicsModel 166 digital spectrophotome-
ter provided with 1-cm matched quartz cells.
2.2. Reagents and Standards. All chemicals and reagents used
were of analytical reagent grade, and distilled water was used
throughout the investigation.
(i) p-Chloranilic acid (0.05%, w/v): it was freshly pre-
pared by dissolving 0.05 g p-chloranilic acid (Rolex,
Mumbai, India) in 100mL acetone.
(ii) 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (0.1%,
w/v): it was prepared by dissolving 0.1 g 2,3-dichloro-
5,6-dicyano-1,4-benzoquinone (Avra synthesis Pvt.
Ltd., Hyderabad, India) in 100mL acetonitrile.
(iii) Standard RSP solution: pharmaceutical grade RSP,
certi�ed to be ��.��% pure, was received from Cipla
India Ltd., Mumbai, India, as a gi sample and was
used as such. A stock standard solution equivalent to
100 𝜇𝜇g/mL of RSPwas prepared separately by dissolv-
ing 10mg of the pure drug in 100mL methanol in
methodA and in 100mL dichloromethane inmethod
B. Working solutions were prepared as required by
dilution with respective solvents.
Pharmaceutical formulations of RSP such as Respidon
(Torrent (Mind)) and Rispond (Micro Synapse) were pur-
chased from local markets.
2.3. General Procedures for Calibration Graph
2.3.1. Method A. An aliquot of standard solution contain-
ing 0.0, 0.25, 0.5, 1.0, 1.5,… , 5.0mL (50 𝜇𝜇g/mL) of RSP was
transferred into a series of 10mL-calibrated �asks. To this
solution was added 3.5mL 0.05% p-CA, then shaken well,
and the contents were diluted to the mark with methanol
and mixed well. e absorbance of the bright pink-colored
complex was measured at 530 nm aer 5min against the
reagent blank prepared similarly, but without drug content.
2.3.2.MethodB. Aliquots of a standard drug solution ranging
0.0, 0.5, 1.0, 1.5, 2.0… , 5.0mL (100 𝜇𝜇g/mL) were taken in a
series of 10mL-calibrated �asks.en, to each �ask 1.5mL of
0.1%DDQwas added.e contents were diluted to the mark
with dichloromethane and mixed well, and the absorbance
of the colored product was measured at 460 nm against the
reagent blank. e amount of RSP present in the sample was
computed from calibration curve or the regression equation.
2.4. Procedure for Pharmaceutical Preparations. irty
tablets each containing 1mg of RSP were weighed and �nely
powdered. An accurately weighed amount of the powder
equivalent to 10mg of RSP was transferred separately into
100mL-calibrated �asks and 10mL each of methanol for
method A and dichloromethane for method B was added.
e content was shaken for about 30min; the volume was
diluted to the mark with respective solvents and mixed
well and �ltered using a Whatman �o. 41 �lter paper. e
�ltrate containing RSP (at a concentration of 100𝜇𝜇g/mL) was
subjected to analysis by the procedures described above.
2.5. Procedure for the Analysis of Placebo Blank and Synthetic
Mixture. A placebo blank containing starch (10mg), acacia
(15mg), hydroxyl cellulose (10mg), sodium citrate (5mg),
talc (15mg), magnesium stearate (20mg), and sodium algi-
nate (10mg) was prepared by combining all components to
form a homogeneous mixture, and its solution was prepared
as described under “Procedure for pharmaceutical prepara-
tions” and was subjected to analysis by following the general
procedures. A synthetic mixture was separately prepared by
adding pure RSP (20mg) to placebo blank, and the extract
was prepared by diluting to give RSP (100𝜇𝜇g/mL) and was
used in both methods A and B, respectively.
Synthetic mixture solution prepared above was taken
at three different concentrations equivalent to 5, 10, and
15 𝜇𝜇g/mL in method A and 10, 20, and 30 𝜇𝜇g/mL in method
B and was subjected to analysis by following the general
procedures.e results of the study indicate that the common
tablet excipients did not interfere in the assay.
2.6. Stoichiometry. Job’s method of continuous variation
[15] was employed to establish the stoichiometry of the
colored products.e solutions equivalent to 1.22 × 10−4 and
2.44 × 10−4M RSP were prepared. Further, 1.22 × 10−4M
p-CA and 2.44 × 10−4M DDQ solutions were prepared in
acetone and acetonitrile, respectively. A series of solutions
were mixed in complimentary proportions; in method A,
the volume was completed up to the mark using methanol,
and with dichloromethane in method B. e absorbances
of the resulting solutions were measured at their respective
wavelengths (𝜆𝜆max) against the reagent blank under the
similar conditions. Job’s method of continuous variations
graph for the reaction between RSP and p-CA or DDQ
(Figure 2) shows that the interaction occurs on an equimolar
basis via the formation of charge-transfer complexes in the
ratio 1 : 1 (RSP : p-CA or DDQ).
3. Results and Discussion
3.1. Chemistry of the Colored Product. e methods involve
charge-transfer (C-T) complex formation between the basic
nitrogenous RSP as 𝑛𝑛-donor and p-chloranilic acid (p-
CA) and DDQ as 𝜋𝜋-acceptors in polar solvents. In each
















































S 1: Proposed reaction scheme for method A.
case, the formed charge-transfer complex was subsequently
dissociated into radical anions, which are colored species.
In method A, an intense bright-pink-colored product was
formed by the interaction of donor 𝑛𝑛-electrons of RSP,
and 𝜋𝜋-acceptor p-CA in acetone-methanol solvent system
showed absorption maxima at 530 nm due to the formation
of the corresponding p-CA radical anion.ADDQ-RSP charge
transfer complex exhibits a maximum absorption at 460 nm;
this is due to the formation ofDDQradical anion arising from
the complete transfer of 𝑛𝑛-electrons from RSP to acceptor
DDQ in acetonitrile-dichloromethane solvent, in method B.
In polar solvents such as methanol or dichloromethane,
complete electron transfer from the donor to the acceptor
moiety takes place with the formation of intensely colored
radical anions [16], as per the following equation:
D̈ + A⟶󶁡󶁡D̈⟶ A󶁱󶁱
CT complex
Polar Solvent




us, p-CA and DDQ were used as reagents in the
proposedmethods A and B, respectively, for the estimation of
RSP. e possible reaction pathway for RSP-p-CA and RSP-
DDQ complexes was proposed and depicted in Schemes 1
and 2, respectively.
e reaction stoichiometry between RSP and p-CA or













































S 2: Proposed reaction scheme for method B.
variations. Job’s plot (Figure 2) reached a maximum value
at a mole fraction of 0.5 which suggested a donor (RSP) to
acceptor (p-CA or DDQ) ratio of 1 : 1. is indicated the
presence of 𝑛𝑛-donating center in the RSP base for charge
transfer complexation reaction.
3.2. Optimization of Experimental Parameters. e factors
affecting the formation of charge-transfer complexation,
reproducibility, sensitivity, and adherence to Beer’s law were
investigated and are reported below.
3.2.1. Effect of 𝑝𝑝-CA Concentration. In order to study the
effect of the volume of the reagent on the absorbance of the
charge transfer complex, varying volumes of 0.05% p-CA
were mixed with 10𝜇𝜇g/mL drug in a 10mL-calibrated �ask
and diluted to volume with methanol. Highest absorbance
was obtained with 3.0mL, which remained unaffected by
further addition of p-CA. Hence, 3.5mL of the reagent was
used for the determination of RSP in method A.
3.2.2. Effect of DDQConcentration. To establish the optimum
experimental condition, risperidone (10𝜇𝜇g/mL) was allowed
to react with different volumes (0–3mL) of 0.1%DDQ.High-
est absorbance was obtained with 1.0mL, which remained
unaffected by further addition of DDQ. us, a volume of
1.5mL of DDQ was used for the determination of RSP in
method B.
















Mole fraction of RSP
(a)
(b)
F 2: Job’s plot for stoichiometric ratio for (a) (RSP) and (p-CA)
= (1.22 × 10−4 M) and (b) (RSP) and (DDQ) = (2.44 × 10−4 M).
T 1: Analytical and regression parameters of the proposed
methods.
Parameter Method A Method B
𝜆𝜆max nm 530 460
Beer’s law range
(𝜇𝜇g/mL ) 0–25 0–50
Molar absorptivity (𝜀𝜀𝜀,
(Lmol/cm) 1.29 × 10




Intercept (𝑎𝑎) 0.0152 0.0097
Slope (𝑏𝑏) 0.0296 0.0104
Correlation coefficient (𝑟𝑟) 0.997 0.997
𝑆𝑆𝑎𝑎 0.0325 0.0216
𝑆𝑆𝑏𝑏 0.0014 0.0005
LOQ (𝜇𝜇g/mL) 0.6521 1.6884
LOD (𝜇𝜇g/mL) 0.2152 0.5572
∗𝑦𝑦 𝑦 𝑎𝑎𝑦𝑏𝑏𝑦𝑦, where 𝑐𝑐 is the concentration of RSP in𝜇𝜇g/mL,𝑦𝑦 is the absorbance
at the respective 𝜆𝜆max, 𝑆𝑆𝑎𝑎 is the standard deviation of the intercept, and 𝑆𝑆𝑏𝑏 is
the standard deviation of the slope.
3.2.3. Effect of Time and Stability of the Complex. e
optimum reaction time was evaluated by monitoring the
color development upon the addition of reagent solution to
RSP at room temperature. It was observed that the reaction
got stabilized within 5 and 2min in methods A and B,
respectively. e developed color was remained stable for
60min at room temperature for both the methods.
3.3. Method Validation. According to the ICH guidelines
[17], both the methods were validated for linearity and
sensitivity, limit of detection (LOD) and limit of quantitation
(LOQ), precision, accuracy, selectivity, and recovery.
3.3.1. Linearity, Sensitivity, Limits of Detection, and Quan-
ti�cation. To establish the linearity, accuracy, and precision
under optimized experimental conditions for both methods
A and B. A linear correlation was found between the
absorbance at respective wavelengths, and concentrations of
RSP in the ranges are given in Table 1. Regression analysis
of the calibration curve using the method of least squares
was made to calculate the slope (𝑏𝑏), intercept (𝑎𝑎), and
correlation coefficient (𝑟𝑟) for each method (methods A and
B), and the values are presented in Table 1. e optical
characteristics such as absorption maxima, Beer’s law limit,
molar absorptivity, and Sandell’s sensitivity values of two
methods are also given in Table 1.
e limit of detection (LOD) and limit of quantitation
(LOQ) were evaluated as per ICH guidelines using the
following equations:
LOD 𝑦 3.3 × 𝜎𝜎
𝑠𝑠
,




where 𝜎𝜎 is the standard deviation (𝑛𝑛 𝑦 𝑛) of reagent blank
determination, and 𝑠𝑠 is the slope of the calibration curve.
3.3.2. Precision and Accuracy. e precision and accuracy
(intra-day and inter-day) of the methods developed were
evaluated by replicate analysis of drug samples at three
different concentrations (low, medium, and high) (Table 2)
within the working limits, each being repeated �ve times.
e RE (%) and RSD (%) values of both intra and inter-day
studies were less than 2.0 and showed the best appraisal of the
procedures in daily use:
RE% 𝑦 󶁥󶁥 founded − addedadded 󶁵󶁵 × 100. (3)
e analytical results obtained from this investigation are
summarized in Table 2. e values of percentage relative
error between the concentrations of RSP for taken and
found showed the high accuracy of the methods. e results
obtained are presented in Table 2 and showed that the
accuracy is good.
3.3.3. Application to Analysis of Pharmaceutical Samples. To
check the validity of the proposed charge-transfer spec-
trophotometric methods, RSP was determined in some com-
mercial formulations. e result obtained from the determi-
nation is in close agreement between the results obtained by
the proposed methods and the label claim. Statistical analysis
of the results using Student’s 𝑡𝑡-test for accuracy and F-test
for precision revealed no signi�cant difference between the
proposed methods and the literature method [12] at the 95%
con�dence level with respect to accuracy and precision (Table
3).
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T 2: Evaluation of accuracy and precision.
Method RSP taken, 𝜇𝜇g/mL Intra-day accuracy and precision Inter-day accuracy and precision
RSP found∗, 𝜇𝜇g/mL % RE % RSD RSP found, 𝜇𝜇g/mL % RE % RSD
Method A
5 4.98 0.43 0.41 5.03 −0.49 0.23
15 14.89 0.74 0.39 15.05 −0.33 0.24
20 19.93 0.35 0.28 20.14 −0.67 0.39
Method B
5 4.98 0.42 0.79 5.11 −2.28 0.79
20 19.78 0.94 0.35 20.03 −0.12 0.39
40 39.89 0.28 0.27 40.12 −0.29 0.53
RE: relative error; RSD: relative standard deviation.
∗Mean value of 5 determinations.
At the 95% con�dence level for 4 degrees of freedom.
T 3: Results of determination of RSP in tablets and statistical comparison with the reference method.
Tablet brand name Nominal amount mg per tablet Found
∗∗ (% of nominal amount ± SD)
Reference method [12] Method A Method B
Respidona 1mg 102.0 ± 0.18 100.18 ± 0.14 100.92 ± 0.45
𝑡𝑡 𝑡 𝑡𝑡𝑡𝑡, 𝐹𝐹 𝑡 𝐹𝑡𝑡𝐹 𝑡𝑡 𝑡 𝑡𝑡𝑡𝑡, 𝐹𝐹 𝑡 𝑡𝑡𝑡𝐹
Rispondb 1mg 101.8 ± 0.24 99.28 ± 0.19 101.16 ± 0.45
𝑡𝑡 𝑡 𝐹𝑡𝑡𝑡, 𝐹𝐹 𝑡 𝑡𝑡𝑡𝑡 𝑡𝑡 𝑡 𝐹𝑡𝑡𝑡, 𝐹𝐹 𝑡 𝐹𝑡𝑡𝑡
Marketed by: a(torrent (mind)), b(micro synapse); ∗∗mean value of �ve determinations.
Tabulated 𝑡𝑡 and 𝐹𝐹 values at 95% con�dence level are 2.77 and 6.39, respectively.
T 4: Results of recovery experiments via the standard addition technique.
Tablet brand name





















5 5 9.97 99𝑡𝑡𝑡 ± 𝑡𝑡𝐹9 10 10 19.99 99𝑡𝑡𝑡 ± 𝑡𝑡𝑡𝑡
5 10 15.10 𝐹𝑡𝑡𝑡9𝐹 ± 𝑡𝑡𝐹𝐹 10 20 30.25 𝐹𝑡𝐹𝑡𝑡𝐹 ± 𝑡𝑡𝐹𝑡
5 15 20.08 𝐹𝑡𝑡𝑡𝑡𝑡 ± 𝑡𝑡𝐹𝐹 10 30 40.50 𝐹𝑡𝐹𝑡𝑡𝑡 ± 𝑡𝑡𝑡𝑡
Rispond
(micro synapse)
5 5 9.92 9𝑡𝑡𝐹𝑡 ± 𝑡𝑡𝐹𝑡 10 10 20.02 𝐹𝑡𝑡𝑡𝐹9 ± 𝑡𝑡𝑡𝑡
5 10 15.02 𝐹𝑡𝑡𝑡𝐹𝑡 ± 𝑡𝑡𝑡𝐹 10 20 30.27 𝐹𝑡𝐹𝑡𝐹𝑡 ± 𝑡𝑡9𝑡
5 15 19.89 99𝑡𝑡𝑡 ± 𝑡𝑡𝐹9 10 30 40.59 𝐹𝑡𝐹𝑡9𝑡 ± 𝑡𝑡𝐹𝑡
∗
Mean value of three measurements.
3.3.4. Recovery Study by Standard Addition Technique. e
accuracy and precision of the proposed methods for the
determination of RSP in commercial sample were further
ascertained by performing recovery studies. In this study,
preanalyzed tablet powder was spiked with pure drug at
three different concentrations, and the total was found by the
proposed methods. Each determination was repeated three
times. e recovery of the pure drug added was quantitative
and revealed that coformulated substances did not interfere in
the determination.e results of recovery study are compiled
in Table 4.
4. Conclusions
epresent paper describes two simple, accurate, precise, and
sensitive extraction-free spectrophotometric methods for the
determination of risperidone in bulk drug and in tablet.
e methods rely on the use of simple and cost-effective
chemicals in both the methods and can be successfully
applied to the routine estimation of risperidone in bulk and
tablet dosage forms. From the calculated 𝑡𝑡- and 𝐹𝐹 values at
the 95% con�dence level, it is clear that the results obtained
by the proposed methods are in good agreement with those
obtained by the reference method [12]. e small values of
RE and RSD indicate the reliability, accuracy, and precision
of suggested procedures.e results obtained in Tables 3 and
4 are considered to be of high accuracy, and, therefore, these
methods can be recommended for the routine analysis of
risperidone in quality control laboratories.
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